Galvanize Therapeutics closed a $130 million Series D led by HealthQuest Capital to expand sales of its Aliya tissue-ablation system in the United States, the company announced November 16. Galvanize says physicians have performed more than 4,000 procedures with its technology.

Aliya uses short electrical pulses to destroy target cells without heating tissue. Physicians deliver the energy through a needle inserted through the skin or through an endoscope. The endoscopic setup is designed to let doctors sample tissue and perform ablation during the same anesthesia session.

Galvanize announced the first commercial procedures with its upgraded Aliya EX generator in August, following FDA clearance in May. The company says the new system can produce an ablation zone up to twice the diameter of its predecessor. Its clearance covers surgical ablation of soft tissue, without a disease-specific treatment indication.

The round is 30% larger than Galvanize’s $100 million Series C, led by Sofinnova Partners in September 2025. That financing also marked Doug Godshall’s move into the CEO role; he previously led Shockwave Medical.

The proceeds will also support clinical research, new PEF devices and development of RheOx, Galvanize’s chronic-bronchitis system. RheOx is designed to target abnormal mucus-producing cells in the airways and remains restricted to investigational use in the United States.

Sources
1Galvanize Series D announcement ↗
2Galvanize Series C announcement, September 2025 ↗
3First commercial Aliya EX procedures, August 2026 ↗
4Aliya EX delivery methods and regulatory scope ↗
5RheOx product and investigational status ↗
6Exploratory Aliya research and its limitations ↗
7Forge company-status reference ↗